Comparison · NCT01699178-deaths
Oral TU vs Transdermal T-gel: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Oral TU vs Transdermal T-gel: deaths from any cause. Trial comparisons, record NCT01699178-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01699178-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0418 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0393 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.0393 | 0.0418 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to harm | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Oral TU | Subjects treated with Oral TU with a measurement taken after approximately 365 days of treatment are used for safety laboratory values for comparisons to baseline. All subjects who received at least one dose of study drug were included in the reporting of treatment emergent adverse events. | 0 | 88 | EG000 |
| Group 2 | Transdermal T-gel | Subjects treated with Transdermal T-gel with a measurement taken after approximately 365 days of treatment are used for safety laboratory values for comparisons to baseline. All subjects who received at least one dose of study drug were included in the reporting of treatment emergent adverse events. | 0 | 94 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- 365 days
Source ClinicalTrials.gov
Trial
- Title
- Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
- NCT number
- NCT01699178
- Phases
- PHASE3
- Conditions
- Male Hypogonadism
- Interventions
- Oral testosterone undecanoate, Transdermal testosterone gel (AndroGel)
- Lead sponsor
- Clarus Therapeutics, Inc.
- Results first posted
- 2018-10-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01699178?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01699178-deaths